



SUVEN Life Sciences Ltd

Communication to investors **September 2015**

10-Nov-15

2015-16 Q2 results



Risk statement

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause these statements to differ materially including outsourcing trends, economic conditions, dependence on collaborative programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.



FINANCIAL QUICK VIEW

		FY 2015-16 Q2 to Q1	FY 2015-16 HY Sep 15
Growth in revenue		15.55%	-19.47%
Growth in PAT		22.23%	-24.53%
Growth in EBIDTA		21.27%	-28.94%
Growth in Pre-R&D EBIDTA		12.01%	-17.75%
Increase in R&D Costs		-5.48%	24.30%
R&D to sales		12.29%	13.56%





MAJOR PROFITABILITY RATIOS



	Q2 Sep 15	HY Sep 15
PAT to Income	20.18%	19.67%
EBIDTA to Income	29.80%	29.15%
Cash Flow to Income	23.85%	22.90%
Pre-R&D EBITDA to Income	42.09%	42.71%




Q2 to Q1 COMPARISON





REVENUE COMPARISON




10-Nov-15

2015-16 Q2 results




PAT COMPARISON



10-Nov-15

2015-16 Q2 results


EBIDTA COMPARISON



10-Nov-15

2015-16 Q2 results

R & D – EXPENDITURE




10-Nov-15

2015-16 Q2 results



PRE-R&D EBIDTA




10-Nov-15

2015-16 Q2 results



PRE-R&D CASHFLOW



10-Nov-15

2015-16 Q2 results



FINANCIAL SNAPSHOT

All figures are in INR Million, other than ratios and EPS

	2015-16 Q2	2015-16 Q1	Growth %	2014-15 Q2	Growth %	2015-16 1HY	2014-15 1HY	Growth %
Income	1,225.49	1,060.57	15.55%	1,412.51	-13.24%	2,286.06	2,838.62	-19.47%
Pre-R&D EBITDA	515.83	460.51	12.01%	507.97	1.55%	976.34	1,187.07	-17.75%
Pre-R&D EBITDA Margin	42.09%	43.42%		35.96%		42.71%	41.82%	
EBITDA	365.20	301.15	21.27%	373.22	-2.15%	666.35	937.69	-28.94%
EBITDA Margin	29.80%	28.39%		26.42%		29.15%	33.03%	
EBIT	320.22	272.10	17.69%	341.08	-6.12%	592.32	866.21	-31.62%
EBIT Margin	26.13%	25.66%		24.15%		25.91%	30.52%	
Financing costs	13.95	9.22		13.30		23.18	24.94	
Taxes	58.98	60.57		79.42		119.55	245.52	
Net Profit after tax	247.29	202.31	22.23%	248.37	-0.43%	449.59	595.75	-24.53%
NP Margin	20.18%	19.08%		17.58%		19.67%	20.99%	
EPS (basic & diluted not annualised)	1.94	1.59		2.13		3.53	5.10	
Paid up share capital (One Rupee Share)	127.28	127.28		116.83		127.28	116.83	
Depreciation	44.98	29.05		32.14		74.03	71.48	
R&D expenses	150.63	159.36	-5.48%	134.75	11.78%	309.99	249.38	24.30%

10-Nov-15

2015-16 Q2 results

News Release



- Suven secures five Product Patents in China, Israel, Mexico, Singapore and Sri Lanka
- Suven secures three Product Patents in Canada and China
- Suven bags Pharmexcil's "Gold Patent Award"
- Suven secures three Product Patents in New Zealand, Singapore and USA
- Suven secures five Product Patents for their NCE's in Australia, China, Europe, South Korea and USA
- Suven facility at JNPC, Vishakapatnam, Andhra Pradesh has commenced commercial operations during this quarter



News Release

- SUVN-D4010 for Cognition in Alzheimer's disease commenced Phase 1 Clinical Trial in USA under US-IND126099 in September 2015
- Suven participated at Society for Neuroscience (SFN-2015) Chicago, USA held during October 17-21 and presented data on several of their NCE's
- Suven presented at Bio-Europe 2015 Partnering conference held during November 2-4, 2015 in Munich, Germany
- Suven presented at 8th CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) Conference held during November 5-7, 2015 at Barcelona, Spain
- Based on the authorization during last Board meeting, Suven has created a wholly owned subsidiary, **Suven, Inc.**, a Delaware Company in USA and the same become operational from October 2015